TherapeuticsMD (NASDAQ:TXMD) Posts Earnings Results

TherapeuticsMD (NASDAQ:TXMD) issued its quarterly earnings results on Wednesday. The company reported $0.01 earnings per share (EPS) for the quarter, FiscalAI reports. TherapeuticsMD had a negative return on equity of 2.01% and a negative net margin of 17.94%.The firm had revenue of $0.78 million for the quarter.

TherapeuticsMD Price Performance

NASDAQ TXMD traded down $0.06 on Thursday, hitting $1.62. 152,669 shares of the company’s stock were exchanged, compared to its average volume of 230,786. The firm’s 50-day moving average price is $1.15 and its two-hundred day moving average price is $1.19. TherapeuticsMD has a fifty-two week low of $0.70 and a fifty-two week high of $2.44. The firm has a market cap of $18.75 million, a price-to-earnings ratio of -27.00 and a beta of 0.53.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of TherapeuticsMD in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.